Navigation Links
ChemoCentryx Announces 2011 Fourth Quarter and Full Year Financial Results
Date:3/30/2012

not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ChemoCentryx's Annual Report on Form 10-K, which we intend to file with the Securities and Exchange Commission tomorrow and which will be available from the SEC's website (www.sec.gov) and on ChemoCentryx's website (www.ChemoCentryx.com) under the heading "Investor Relations." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

CCXI – GContacts:Susan M. Kanaya

Burns McClellanSenior Vice President, Finance and

Media InquiriesChief Financial Officer or

Kathy Nugent, Ph.D.Markus J. Cappel, Ph.D.

212-213-0006Chief Business Officer

knugent@burnsmc.com 650-210-2900investor@chemocentryx.comChemoCentryx, Inc. Consolidated Statement of Operations Data (in thousands, except share and per share data) Three Months Ended December 31, Year Ended December 31, 2011 2010 2011 2010 Consolidated Statement of Operations Data: Revenues: Collaborative research and development revenue from related party  

$
26,052$
3,115$
31,673$
34,861 Total revenues:

26,05213,11531,67334,861 Operating expenses: Research and development  

5,4458,14228,35933,527 General and administrative  

1,8941,9297,6157,292 Total operating expenses  

7,33910,07135,97440,819 Income (loss) from operations  

18,7133,
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... SAN FRANCISCO, Calif. , May 28, 2015 /PRNewswire/ ... treatment of cancer, today announced that Sean McCarthy ... the upcoming Jefferies 2015 Global Healthcare Conference ... p.m. EDT on Tuesday, June 2, 2015. Dr. McCarthy ... the company,s Precision cancer immunotherapy and Probody drug conjugate ...
(Date:5/28/2015)... 28, 2015  Shareholder rights law firm Robbins ... officers and directors of Eleven Biotherapeutics, Inc. (NASDAQGM: EBIO) ... is a clinical-stage biopharmaceutical company that engages in ... treat eye diseases, primarily in the ... this press release on the law firm,s Shareholder ...
(Date:5/28/2015)... Eli Lilly and Company (NYSE: LLY ) and Incyte ... June 11 to discuss data from the first two pivotal ... two trials, RA-BEACON and RA-BUILD, will be presented on June ... in Rome, Italy . The ... Time. The live audio webcast can be accessed through a ...
Breaking Medicine Technology:Robbins Arroyo LLP Is Investigating the Officers and Directors of Eleven Biotherapeutics, Inc. (EBIO) on Behalf of Shareholders 2Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 2Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 3
(Date:5/28/2015)... Texas (PRWEB) May 28, 2015 Park Cities ... Group Dog Training class starting Saturday, June 6th ... the courtyard of 5831 McCommas Blvd in Dallas, with a ... classes will run for five weeks, with no class being ... the class is $135. , In this Intermediate-to-Advanced level class, ...
(Date:5/28/2015)... Three years ago, Dr. Jeffrey Gosin announced ... Vascular & Vein Center! Dr. Gosin’s center is ... is his mission to provide the highest quality care in ... Dr. Jeffrey Gosin is Board Certified in Surgery and Vascular ... and Jefferson Medical College. He completed a General Surgery residency ...
(Date:5/28/2015)... May 28, 2015 AMVETS leaders this ... prize winner Robert Davis of Newark, Del. AMVETS National ... him on winning the $10,000 sweepstakes grand prize. , ... 100,000 entries from around the country for prizes ranging ... took place on May 21 at the AMVETS National ...
(Date:5/28/2015)... Medelis, Inc., a specialty oncology CRO , ... the role of president. , “ Bill Taaffe has ... said Larry Flanagan, Medelis’ CEO and co-founder. “He will be ... phase of growth.” , Taaffe joined ICON’s U.S. clinical ... to over 4,500 employees, achieving 12 consecutive years of growth ...
(Date:5/28/2015)... 28, 2015 ISMETT , a leading ... boosted the Sicilian economy by €132.5 million in expenditure in ... of more than €73 million by retaining patients who otherwise ... a new study by the Battelle Memorial Institute. At the ... training and advanced health care management that is transforming Sicily ...
Breaking Medicine News(10 mins):Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 3Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 2Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 3Health News:AMVETS Announces Summer Sweepstakes Winners 2Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 3
... Holohan HealthDay Reporter , WEDNESDAY, Jan. 5 (HealthDay ... of chickenpox-related hospitalizations in the United States for the first ... And a second study has found that the ... Centers for Disease Control and Prevention in 2006, may offer ...
... doses of the varicella, or chickenpox, vaccine provide excellent protection ... severe disease. To be published in the February 1 issue ... support the two-dose vaccine regimen recommended in the United States ... study online.) The Centers for Disease Control and Prevention ...
... HealthDay Reporter , TUESDAY, Jan. 4 (HealthDay News) -- Up ... an increase that translates into many fewer injuries and deaths ... the first state law requiring seat belts was passed in ... But now, according to the U.S. Centers for Disease Control ...
... HealthDay Reporter , TUESDAY, Jan. 4 (HealthDay News) -- ... of the drug Avastin to treat breast cancer, a new ... odds of congestive heart failure in these patients. The ... Clinical Oncology , included almost 4,000 patients and found a ...
... DURHAM, N.C. A tiny light source and sensors at ... way to identify pre-cancerous cells in the lining of the ... successfully tested on patients during a clinical trial at the ... the promise of being a less invasive method for testing ...
... there is often concern about possible effects on the ... birth defects (thalidomide being a notorious example), and others ... about most drugs, level of risk. Researchers in the ... preclinical model for predicting a drug,s teratogenicity (tendency to ...
Cached Medicine News:Health News:Chickenpox Vaccine Cuts Hospitalization Rates: Study 2Health News:Chickenpox Vaccine Cuts Hospitalization Rates: Study 3Health News:Chickenpox Vaccine Cuts Hospitalization Rates: Study 4Health News:Study confirms 2 vaccine doses protect children from chickenpox 2Health News:Six Out of 7 Drivers Use Seat Belts: CDC 2Health News:Six Out of 7 Drivers Use Seat Belts: CDC 3Health News:More Evidence Links Avastin to Heart Failure in Breast Cancer Patients 2Health News:More Evidence Links Avastin to Heart Failure in Breast Cancer Patients 3Health News:Detecting esophageal cancer with light 2Health News:Model predicts a drug's likelihood of causing birth defects 2
... The Techne TC-512 has a graphical touch ... your experiments at the "touch of a ... Wide linear gradient, Touch Screen, Graphical Display, ... Performance, Versatile Block Format, Intuitive Programmin, Free ...
... Techne TC412 is a high performance, high sample ... Features & Benefits include: Flexible block format, ... 8 peltiers, PC networking. Includes a four ... 32 Techne cyclers can be connected and run ...
... a compact design for personal use, yet is able ... up to 32 samples simultaneously. It contains a heating ... to add mineral oil to prevent evaporation of the ... and up to 15 steps can be freely connected ...
... cycler is the smallest footprint two-bay thermal ... ever before. The Disciple instrument ... communications to a computer using a remote ... thermal cycler contains the latest in power ...
Medicine Products: